Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Assets: 2020-2024

Historic Current Assets for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $23.8 million.

  • SAB Biotherapeutics' Current Assets rose 248.15% to $113.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 248.15%. This contributed to the annual value of $23.8 million for FY2024, which is 59.61% down from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Current Assets is $23.8 million, which was down 59.61% from $58.9 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Current Assets registered a high of $58.9 million during FY2023, and its lowest value of $22.1 million during FY2022.
  • For the 3-year period, SAB Biotherapeutics' Current Assets averaged around $34.9 million, with its median value being $23.8 million (2024).
  • Its Current Assets has fluctuated over the past 5 years, first surged by 166.58% in 2023, then plummeted by 59.61% in 2024.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Current Assets stood at $34.5 million in 2020, then skyrocketed by 45.67% to $50.2 million in 2021, then plummeted by 55.97% to $22.1 million in 2022, then surged by 166.58% to $58.9 million in 2023, then crashed by 59.61% to $23.8 million in 2024.